ALNY Alnylam Pharmaceuticals, Inc. - Common Stock
Sobre Alnylam Pharmaceuticals, Inc. - Common Stock Visão geral da empresa da Wikipedia
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Ler mais
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
History
The company is a spin-off from the Max Planck Institute for Biophysical Chemistry. In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion's belt. The spelling was modified to make it unique. In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders, and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy. In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. and also partnered with Ionis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.
In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus. In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's disease focused research. In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection. In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia. In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.
In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration. In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock. In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.
In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.
In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.
On October 10, 2018, Alnylam appoints Margaret Hamburg to Board of Directors. Prior to this, from May 2009 to April 2015, she serves as Commissioner of the U.S. Food and Drug Administration (FDA).
In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors. In 2021, it was announced that Maraganore would step down as CEO, to be succeeded by the company's chief operating officer, Yvonne Greenstreet, on January 1, 2022.
In December 2021, Alnylam submitted a clinical trial authorisation (CTA) application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom to initiate a Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical trials currently underway. Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023.
In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.
Products
In 2016, Alnylam Pharmaceuticals had 18 potential treatments in various development stages in genetic medicine, cardiometabolic disease and hepatic infectious disease.
Patisiran
In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with the compromised nervous system condition of familial amyloidotic polyneuropathy (FAP).
In August 2018, with its commercial name Onpattro, patisiran received the U.S. regulatory approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis.
FDA on patisiran for cardiomyopathy
In September 2023, the FDA raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM). The FDA's Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13, 2023. Although the APOLLO-B study met key endpoints, the FDA questioned the clinical significance of the results particularly for patients not on background therapy with tafamidis. The FDA is seeking the committee's input on the clinical meaningfulness and patient populations for patisiran use potentially challenging Pfizer's tafamidis dominance in ATTR-CM treatment. A decision on Alnylam's application is expected by October 8, 2023. Patisiran was previously approved in 2018 for hereditary ATTR amyloidosis polyneuropathy, becoming the first RNA interference therapeutic approved by the FDA. The committee meeting chose to deny approval for the treatment of cardiomyopathy of ATTR amyloidosis with patisiran. Note that while patisiran was denied for the indication of cardiomyopathy, it remains an FDA approved treatment for polyneuropathy.
Vutrisiran
Alnylam went on to pursue the development of vutrisiran, which received FDA approval in 2022 and accounted for the majority of reported profit compared to patisiran/Onpattro in 2025.
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
ALNY Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
ALNY Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
ALNY Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
- Compra forte 8 21,6%
- Compra 21 56,8%
- Manter 8 21,6%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
26 analistas · 2026-08-21Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Junho de 2026 | $1.21 | $1.59 | -0.38% |
| 31 de Março de 2026 | $1.51 | $0.98 | 0.53% |
| 31 de Dezembro de 2025 | $0.82 | $1.15 | -0.33% |
| 30 de Setembro de 2025 | $2.11 | $0.76 | 1.3% |
| 30 de Junho de 2025 | $-0.51 | $-0.73 | 0.22% |
| 31 de Março de 2025 | $-0.44 | $-1.03 | 0.59% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| RVMD | — | — | — | — | — | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 17
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | · | · | |
| Cost of Revenue | $677M | $307M | $268M | $140M | $115M | $74M | $25M | $2M | $0 | · | · | · | |
| R&D Expense | $1.32B | $1.13B | $1.00B | $883M | $792M | $655M | $655M | $505M | $391M | $382M | $276M | $190M | |
| SG&A Expense | $1.21B | $976M | $796M | $771M | $621M | $588M | $479M | $382M | $199M | $89M | $61M | $45M | |
| Operating Expenses | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B | $1.16B | $890M | $590M | $472M | $337M | $456M | |
| Operating Income | $502M | $-177M | $-282M | $-785M | $-709M | $-828M | $-939M | $-815M | $-500M | $-425M | $-296M | $-405M | |
| Interest Expense | · | · | $121M | $156M | $143M | $84M | $0 | $0 | · | · | · | · | |
| Interest Income | $111M | $122M | $96M | $25M | $2M | $12M | $33M | $29M | · | · | · | · | |
| Other Non-op | $5M | $-181M | $-126M | $-134M | $-2M | $57M | $21M | $25M | $-3M | $6M | $76.0K | $2M | |
| Pretax Income | $323M | $-377M | $-434M | $-1.13B | $-852M | $-856M | $-885M | $-761M | $-491M | $-410M | $-290M | $-401M | |
| Income Tax | $9M | $-99M | $7M | $4M | $680.0K | $3M | $863.0K | $823.0K | $0 | $0 | $0 | $-40M | |
| Net Income | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| Shares (Basic) | 131,004,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| Shares (Diluted) | 134,684,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| EBITDA | $557M | $-120M | $-228M | $-741M | $-661M | $-794M | $-922M | $-808M | $-487M | $-409M | $-277M | $-393M |
Balanço Patrimonial 23
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $966M | $813M | $866M | $820M | $497M | $547M | $420M | $645M | $194M | $181M | $75M | |
| Receivables | $778M | $405M | $328M | $238M | $199M | $102M | $43M | $19M | $34M | $23M | $8M | $40M | |
| Inventory | $83M | $79M | $89M | $129M | $86M | $75M | $56M | $24M | · | · | · | · | |
| Prepaid Expense | $282M | $117M | $126M | $133M | $88M | $63M | $80M | $74M | $40M | $22M | $17M | $10M | |
| Current Assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B | $2.61B | $1.72B | $1.20B | $1.76B | $672M | $1.11B | $746M | |
| PP&E (Net) | $513M | $503M | $526M | $523M | $502M | $465M | $425M | $321M | $182M | $115M | $28M | $22M | |
| PP&E (Gross) | $836M | $773M | $749M | $697M | $642M | $569M | $501M | $400M | $249M | $176M | $79M | $68M | |
| Accum. Depreciation | $323M | $270M | $223M | $173M | $140M | $104M | $76M | $79M | $67M | $61M | $51M | $46M | |
| Other Non-current Assets | $59M | $65M | $62M | $66M | $60M | $45M | $18M | $9M | $4M | $2M | $1M | · | |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Accounts Payable | $116M | $88M | $56M | $98M | $73M | $52M | $50M | $60M | $28M | $54M | $17M | $15M | |
| Accrued Liabilities | $1.08B | $794M | $713M | $545M | $395M | $356M | $197M | $113M | $72M | $42M | $29M | $24M | |
| Current Liabilities | $1.47B | $1.19B | $968M | $768M | $696M | $585M | $353M | $179M | $144M | $132M | $62M | $95M | |
| Capital Leases | $225M | $230M | $243M | $261M | $281M | $293M | $276M | · | · | · | · | · | |
| Other Non-current Liabilities | $8M | $5M | $308M | $213M | $99M | $38M | $9M | $5M | $4M | $3M | $1M | · | |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956M | $273M | $228M | $343M | $122M | $143M | |
| Long-term Debt | · | · | · | · | $676M | $191M | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $997.0K | $859.0K | $851.0K | $772.0K | |
| Retained Earnings | $-6.70B | $-7.29B | $-7.01B | $-6.57B | $-5.44B | $-4.59B | $-3.73B | $-2.84B | $-2.15B | $-1.66B | $-1.25B | $-957M | |
| AOCI | $-20M | $-35M | $-23M | $-45M | $-33M | $-44M | $-37M | $-33M | $-34M | $-33M | $4M | $49M | |
| Stockholders' Equity | $789M | $67M | $-221M | $-158M | $588M | $1.02B | $1.44B | $1.30B | $1.77B | $920M | $1.26B | $936M | |
| Liabilities + Equity | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Shares Outstanding | 132,376,000 | 129,294,000 | 125,794,000 | 123,925,000 | 120,182,000 | 116,427,000 | 112,188,000 | 101,177,000 | 99,667,000 | 85,941,000 | 85,090,968 | 77,202,753 |
Fluxo de Caixa 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $57M | $54M | $44M | $48M | $35M | $17M | $15M | $12M | $15M | $19M | $12M | |
| Stock-based Comp | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M | $46M | $33M | |
| Deferred Tax | $-2M | $-107M | $-713.0K | $-1M | $-3M | $-3M | $-2M | $-788.0K | $0 | · | · | · | |
| Other Non-cash | $-191M | $48M | $269M | $316M | $614.0K | $72M | $418M | $35M | $2M | $12M | $36M | $150M | |
| Operating Cash Flow | $524M | $-8M | $104M | $-541M | $-642M | $-615M | $-278M | $-563M | $-383M | $-308M | $-189M | $-166M | |
| CapEx | $59M | $34M | $62M | $72M | $76M | $70M | $140M | $127M | $104M | $65M | $13M | $9M | |
| Investing Cash Flow | $436M | $-117M | $-336M | $169M | $-273M | $-436M | $-418M | $273M | $-290M | $143M | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $382M | $0 | $1.14B | · | $496M | · | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $382M | · | $1.14B | · | $496M | · | |
| Financing Cash Flow | $-305M | $294M | $172M | $426M | $1.25B | $995M | $823M | $65M | $1.12B | $178M | · | · | |
| Net Change in Cash | $690M | $154M | $-54M | $46M | $323M | $-51M | $127M | $-224M | $452M | $13M | $106M | $22M | |
| Taxes Paid | $15M | $14M | $6M | $3M | · | · | · | · | · | $111.0K | $66.0K | $-517.0K | |
| Free Cash Flow | $465M | $-43M | $42M | $-613M | $-718M | $-685M | $-419M | $-690M | $-487M | $-372M | $-202M | $-175M | |
| Levered FCF | · | · | $-81M | $-770M | $-861M | $-770M | · | · | · | · | · | · |
Lucratividade 7
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | · | · | · | · | |
| Net Margin | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | · | · | · | · | |
| Pretax Margin | 8.7% | -16.8% | -23.7% | -108.6% | -100.9% | -173.6% | -402.9% | -1015.5% | · | · | · | · | |
| EBITDA Margin | 15.0% | -5.3% | -12.5% | -71.4% | -78.3% | -161.0% | -419.7% | -1079.0% | · | · | · | · | |
| ROA | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% | -23.5% | -48.0% | |
| ROE | 60.4% | -559.4% | 227.8% | 1001.6% | -126.9% | -76.9% | -58.2% | -54.8% | -36.5% | -37.5% | -26.4% | -59.7% | |
| ROIC | 61.7% | -194.3% | 129.9% | 498.0% | -120.6% | -81.8% | -65.4% | -62.6% | · | · | -23.4% | -38.9% |
Liquidez e Solvência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 | 4.5 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 | 1.0 | 1.7 | 2.4 | 4.7 | 1.6 | 3.0 | 1.2 | |
| Interest Coverage | · | · | -2.3 | -5.0 | -5.0 | -9.8 | · | · | · | · | · | · |
Eficiência 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.6 | 0.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | · | · | · | · | |
| Inventory Turnover | 8.4 | 3.7 | 2.5 | 1.3 | 1.4 | 1.2 | 0.6 | 0.1 | · | · | · | · | |
| Receivables Turnover | 6.3 | 6.1 | 6.5 | 4.8 | 5.6 | 6.8 | 7.1 | 2.8 | · | · | · | · |
Taxas de Crescimento 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 53.0% | 38.6% | 54.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 49.8% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 10
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | $100M | $100M | |
| Net Income TTM | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| Market Cap | $52.64B | $30.42B | $24.08B | $29.45B | $20.38B | $15.13B | $12.92B | $7.38B | $12.66B | $3.22B | $8.01B | $7.49B | |
| P/E | 170.7 | -107.9 | -54.4 | -25.6 | -23.6 | -17.4 | -14.2 | · | · | · | · | · | |
| P/S | 14.2 | 13.5 | 13.2 | 28.4 | 24.1 | 30.7 | 58.8 | 98.5 | 140.8 | 68.2 | 80.3 | 75.1 | |
| P/B | 66.7 | 453.5 | -109.1 | -186.1 | 34.6 | 14.9 | 9.0 | 5.7 | 7.2 | 3.5 | 6.3 | 8.0 | |
| P / Tangible Book | 66.7 | 453.5 | · | · | 34.6 | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | 100.4 | -3660.3 | 231.2 | -54.4 | -31.8 | -24.6 | -46.4 | -13.1 | -33.1 | -10.5 | -42.4 | -45.2 | |
| P / FCF | 113.1 | -714.4 | 574.0 | -48.0 | -28.4 | -22.1 | -30.9 | -10.7 | -26.0 | -8.6 | -39.6 | -42.9 | |
| Earnings Yield | 0.59% | -0.93% | -1.8% | -3.9% | -4.2% | -5.7% | -7.0% | · | · | · | · | · |
Demonstração de Resultados 17
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $774M | $594M | $593M | $501M | $660M | $494M | $440M | $751M | $319M | $319M | $335M | $264M | |
| Cost of Revenue | $298M | $208M | $268M | $197M | $142M | $70M | $103M | $82M | $67M | $55M | $72M | $79M | $75M | $41M | $46M | $37M | |
| R&D Expense | $413M | $365M | $372M | $359M | $324M | $265M | $300M | $271M | $294M | $261M | $272M | $253M | $249M | $231M | $262M | $245M | |
| SG&A Expense | $348M | $323M | $325M | $322M | $323M | $240M | $295M | $221M | $248M | $211M | $198M | $199M | $215M | $184M | $210M | $236M | |
| Operating Expenses | $1.06B | $899M | $965M | $881M | $790M | $576M | $698M | $578M | $611M | $538M | $556M | $537M | $549M | $469M | $524M | $522M | |
| Operating Income | $231M | $269M | $132M | $368M | $-16M | $18M | $-105M | $-77M | $49M | $-43M | $-116M | $214M | $-230M | $-150M | $-189M | $-258M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $31M | $30M | $29M | · | $41M | |
| Interest Income | $28M | $27M | $27M | $29M | $27M | $29M | $31M | $32M | $29M | $30M | $30M | $25M | $21M | $19M | $14M | $8M | |
| Other Non-op | $273.0K | $-4M | $135M | $-74M | $9M | $9M | $-81M | $-30M | $-56M | $-15M | $-20M | $-58M | $-35M | $-12M | $-3M | $-38M | |
| Pretax Income | $178M | $222M | $161M | $239M | $-41M | $-2M | $-194M | $-109M | $-11M | $-64M | $-138M | $151M | $-274M | $-172M | $-207M | $-406M | |
| Income Tax | $13M | $16M | $-25M | $-12M | $31M | $16M | $-110M | $3M | $6M | $2M | $183.0K | $3M | $2M | $2M | $472.0K | $-23.0K | |
| Net Income | $164M | $206M | $186M | $251M | $-72M | $-18M | $-84M | $-112M | $-17M | $-66M | $-138M | $148M | $-276M | $-174M | $-207M | $-406M | |
| EPS (Basic) | $1.23 | $1.55 | $1.43 | $1.91 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.09 | $1.18 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| EPS (Diluted) | $1.21 | $1.51 | $1.44 | $1.84 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.06 | $1.15 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| Shares (Basic) | 133,606,000 | 132,893,000 | -260,747,000 | 131,447,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -249,084,000 | 125,220,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| Shares (Diluted) | 138,281,000 | 138,226,000 | -262,968,000 | 137,348,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -255,201,000 | 131,337,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| EBITDA | $231M | $282M | · | $368M | $-16M | $32M | · | $-77M | $49M | $-30M | · | $214M | $-230M | $-136M | · | $-258M |
Balanço Patrimonial 22
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B | $966M | $1.10B | $968M | $682M | $813M | $1.03B | $658M | $672M | $866M | $1.07B | |
| Receivables | $913M | $884M | $778M | $965M | $567M | $418M | $405M | $354M | $309M | $321M | · | $325M | $221M | $219M | · | $185M | |
| Inventory | $97M | $84M | $83M | $75M | $72M | $66M | $79M | $76M | $84M | $94M | · | $96M | $100M | $132M | · | $115M | |
| Prepaid Expense | $302M | $242M | $282M | $188M | $147M | $152M | $117M | $145M | $155M | $202M | · | $158M | $145M | $119M | · | $126M | |
| Current Assets | $4.62B | $4.22B | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | · | $2.99B | $2.52B | $2.54B | · | $2.69B | |
| PP&E (Net) | $554M | $518M | $513M | $502M | $500M | $499M | $503M | $507M | $517M | $523M | · | $526M | $527M | $523M | · | $515M | |
| PP&E (Gross) | · | · | $836M | · | · | · | $773M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $323M | · | · | · | $270M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $65M | $64M | $59M | $56M | $57M | $74M | $65M | $78M | $72M | $67M | · | $75M | $93M | $63M | · | $61M | |
| Total Assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Accounts Payable | $108M | $127M | $116M | $118M | $102M | $97M | $88M | $71M | $74M | $78M | · | $74M | $60M | $62M | · | $41M | |
| Accrued Liabilities | $1.10B | $946M | $1.08B | $1.15B | $919M | $704M | $794M | $946M | $809M | $699M | · | $713M | $599M | $509M | · | $511M | |
| Current Liabilities | $1.51B | $1.35B | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $942M | · | $950M | $789M | $673M | · | $773M | |
| Capital Leases | $210M | $218M | $225M | $223M | $224M | $230M | $230M | $236M | $239M | $238M | · | $248M | $253M | $259M | · | $266M | |
| Other Non-current Liabilities | $9M | $8M | $8M | $10M | $11M | $6M | $5M | $357M | $350M | $320M | · | $281M | $257M | $224M | · | $183M | |
| Total Liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | · | $4.00B | $3.81B | $3.65B | · | $3.60B | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Retained Earnings | $-6.33B | $-6.50B | $-6.70B | $-7.16B | $-7.41B | $-7.35B | $-7.29B | $-7.20B | $-7.09B | $-7.08B | · | $-6.87B | $-7.02B | $-6.74B | · | $-6.36B | |
| AOCI | $-32M | $-25M | $-20M | $-22M | $-30M | $-38M | $-35M | $-25M | $-35M | $-27M | · | $-32M | $-37M | $-39M | · | $-44M | |
| Stockholders' Equity | $1.35B | $1.08B | $789M | $234M | $251M | $115M | $67M | $32M | $-3M | $-219M | $-221M | $-166M | $-408M | $-259M | $-158M | $-68M | |
| Liabilities + Equity | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Shares Outstanding | 133,734,000 | 133,444,000 | 132,376,000 | 131,791,000 | 130,977,000 | 130,311,000 | 129,294,000 | 128,841,000 | 128,021,000 | 126,463,000 | 125,794,000 | 125,454,000 | 124,901,000 | 124,241,000 | 123,925,000 | 122,991,000 |
Fluxo de Caixa 12
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $15M | $14M | $13M | $13M | $13M | $14M | $14M | $11M | |
| Stock-based Comp | $87M | $70M | $72M | $108M | $112M | $57M | $92M | $46M | $89M | $45M | $42M | $64M | $76M | $40M | $43M | $128M | |
| Deferred Tax | $3M | $9M | $-27M | $6M | $10M | $10M | $-107M | $-163.0K | $340.0K | $454.0K | · | · | · | · | · | · | |
| Other Non-cash | · | $-229M | · | · | · | $-142M | · | · | · | $-74M | · | · | · | $-46M | · | · | |
| Operating Cash Flow | $327M | $71M | $164M | $325M | $154M | $-120M | $-95M | $44M | $124M | $-82M | $-30M | $359M | $-59M | $-166M | $-132M | $-115M | |
| CapEx | $35M | $22M | $23M | $12M | $14M | $9M | $9M | $4M | $8M | $13M | $15M | $17M | $16M | $14M | $22M | $17M | |
| Investing Cash Flow | $-363M | $-26M | $-37M | $501M | $-141M | $114M | $-53M | $-30M | $34M | $-68M | $-241M | $-11M | $-9M | $-76M | $-140M | $314M | |
| Financing Cash Flow | $36M | $16M | $45M | $-448M | $54M | $46M | $31M | $103M | $131M | $29M | $39M | $33M | $53M | $46M | $63M | $297M | |
| Net Change in Cash | $-3M | $54M | $166M | $377M | $94M | $54M | $-134M | $131M | $286M | $-130M | $-220M | $375M | $-14M | $-194M | $-207M | $498M | |
| Taxes Paid | $12M | $2M | $13M | $1M | $-2M | $3M | · | $5M | $2M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | · | $49M | · | · | · | $-127M | · | · | · | $-94M | · | · | · | $-180M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-131M | · | · | · | $-210M | · | · |
Lucratividade 7
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.9% | 23.0% | · | 29.5% | -2.1% | 3.0% | · | -15.3% | 7.4% | -8.8% | · | 28.5% | -72.1% | -46.9% | · | -97.6% | |
| Net Margin | 12.7% | 17.6% | · | 20.1% | -8.6% | -9.7% | · | -22.3% | -2.6% | -13.3% | · | 19.7% | -86.6% | -54.5% | · | -153.6% | |
| Pretax Margin | 13.8% | 19.0% | · | 19.1% | -4.6% | -7.0% | · | -21.7% | -1.7% | -12.9% | · | 20.1% | -86.0% | -54.0% | · | -153.6% | |
| EBITDA Margin | 17.9% | 24.2% | · | 29.5% | -2.1% | 5.5% | · | -15.3% | 7.4% | -6.0% | · | 28.5% | -72.1% | -42.5% | · | -97.6% | |
| ROA | 3.2% | 4.4% | · | 5.5% | -1.6% | -1.4% | · | -2.8% | -0.46% | -1.8% | · | 4.0% | -8.2% | -5.1% | · | -11.6% | |
| ROE | 20.5% | 34.6% | · | 188.6% | -53.5% | 110.7% | · | 167.1% | 8.2% | 27.6% | · | -126.6% | 237.9% | -245.3% | · | -118.0% | |
| ROIC | 15.8% | 23.2% | · | 165.3% | -12.1% | 21.6% | · | -244.1% | -2397.3% | 20.5% | · | -126.4% | 56.7% | 58.4% | · | 381.5% |
Liquidez e Solvência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.1 | · | 2.5 | 2.8 | 3.0 | · | 2.7 | 3.0 | 3.2 | · | 3.1 | 3.2 | 3.8 | · | 3.5 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.6 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.4 | 1.1 | 1.3 | · | 1.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.2 | · | 6.9 | -7.7 | -5.2 | · | -6.3 |
Eficiência 3
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.5 | 2.8 | · | 2.6 | 1.8 | 0.9 | · | 1.0 | 0.7 | 0.5 | · | 0.8 | 0.8 | 0.4 | · | 0.3 | |
| Receivables Turnover | 1.7 | 1.8 | · | 1.9 | 1.8 | 1.6 | · | 1.5 | 2.5 | 1.8 | · | 2.9 | 1.8 | 1.7 | · | 1.6 |
Avaliação (TTM) 10
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.48B | $3.78B | · | $3.12B | $2.53B | $2.25B | · | $2.41B | $2.22B | $1.88B | · | $1.65B | $1.13B | $1.02B | · | $890M | |
| Net Income TTM | $549M | $373M | · | $55M | $-213M | $-213M | · | $-47M | $-211M | $-368M | · | $-708M | $-1.13B | $-1.10B | · | $-1.13B | |
| Market Cap | $40.26B | $44.15B | · | $60.10B | $42.71B | $35.19B | · | $35.44B | $31.11B | $18.90B | · | $22.22B | $23.72B | $24.89B | · | $24.62B | |
| P/E | 75.1 | 122.5 | · | 1425.0 | -197.6 | -162.7 | · | -743.3 | -142.1 | -50.2 | · | -30.6 | -20.6 | -22.2 | · | -21.5 | |
| P/S | 9.0 | 11.7 | · | 19.3 | 16.9 | 15.6 | · | 14.7 | 14.0 | 10.0 | · | 13.4 | 21.0 | 24.4 | · | 27.7 | |
| P/B | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | -10143.2 | -86.2 | · | -134.0 | -58.1 | -96.0 | · | -364.0 | |
| P / Tangible Book | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 626.2 | · | · | · | -297.4 | · | · | · | -231.9 | · | · | · | -149.5 | · | · | |
| P / FCF | · | 907.2 | · | · | · | -276.4 | · | · | · | -200.0 | · | · | · | -138.0 | · | · | |
| Earnings Yield | 1.3% | 0.82% | · | 0.07% | -0.51% | -0.61% | · | -0.13% | -0.70% | -2.0% | · | -3.3% | -4.9% | -4.5% | · | -4.7% |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $3.71B | $2.25B | $1.83B | $1.04B | $844M |
| Margem Operacional % | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| Lucro líquido | $314M | $-278M | $-440M | $-1.13B | $-853M |
| EPS Diluído | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 |
| Índice de Liquidez Seca | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $465M | $-43M | $42M | $-613M | $-718M |
Últimas notícias Notícias recentes mencionando esta empresa
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Investidores institucionais (13F) 877 declarantes · $27.2B total · Em 30 de Junho de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 92 (-24 vs trimestre anterior) | 77 (-68 vs trimestre anterior) | 336 (+11 vs trimestre anterior) | 263 (+7 vs trimestre anterior) | +2.3M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| Capital World Investors | $3.354.715.611 | 11.144.846 | 12,36% | Ações |
| FMR LLC | $3.108.157.652 | 10.325.076 | 11,45% | Ações |
| Capital Research Global Investors | $2.935.115.324 | 9.750.699 | 10,81% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.968.251.542 | 6.538.390 | 7,25% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.815.053.762 | 6.029.478 | 6,69% | Ações |
| STATE STREET CORP | $1.070.369.060 | 3.555.689 | 3,94% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $686.853.582 | 2.288.725 | 2,53% | Ações |
| NORGES BANK | $683.883.867 | 2.271.813 | 2,52% | Ações |
| WELLINGTON MANAGEMENT GROUP LLP | $614.923.915 | 2.042.733 | 2,26% | Ações |
| Dodge & Cox | $588.631.955 | 1.955.393 | 2,17% | Ações |
| TWO SIGMA INVESTMENTS, LP | $564.713.315 | 1.875.937 | 2,08% | Ações |
| AMERICAN CENTURY COMPANIES INC | $558.098.292 | 1.853.956 | 2,06% | Ações |
| TWO SIGMA ADVISERS, LP | $450.362.484 | 1.132.560 | 1,66% | Ações |
| Clearbridge Investments, LLC | $379.142.285 | 1.259.483 | 1,40% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $269.059.154 | 893.795 | 0,99% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $259.723.265 | 862.782 | 0,96% | Ações |
| Deep Track Capital, LP | $248.349.750 | 825.000 | 0,91% | Ações |
| Qube Research & Technologies Ltd | $240.437.176 | 798.715 | 0,89% | Ações |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $219.642.021 | 729.635 | 0,81% | Ações |
| BANK OF AMERICA CORP /DE/ | $176.408.397 | 586.016 | 0,65% | Ações |
| LOOMIS SAYLES & CO L P | $170.456.431 | 566.244 | 0,63% | Ações |
| BAILLIE GIFFORD & CO | $165.849.468 | 550.940 | 0,61% | Ações |
| ROYAL BANK OF CANADA | $154.998.000 | 514.893 | 0,57% | Ações |
| Polar Capital Holdings Plc | $145.322.534 | 482.751 | 0,54% | Ações |
| Paradigm Biocapital Advisors LP | $144.494.400 | 480.000 | 0,53% | Ações |
| D. E. Shaw & Co., Inc. | $129.533.209 | 430.300 | 0,48% | Opção de compra |
| FIRST TRUST ADVISORS LP | $126.894.361 | 421.534 | 0,47% | Ações |
| Swiss National Bank | $112.609.302 | 374.080 | 0,41% | Ações |
| WELLS FARGO & COMPANY/MN | $111.381.100 | 370.000 | 0,41% | Opção de compra |
| BlackRock, Inc. | $102.807.465 | 341.519 | 0,38% | Ações |
| CANADA PENSION PLAN INVESTMENT BOARD | $100.618.073 | 334.246 | 0,37% | Ações |
| Sumitomo Mitsui Trust Group, Inc. | $97.948.840 | 325.379 | 0,36% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $97.804.647 | 324.900 | 0,36% | Opção de compra |
| Legal & General Group Plc | $97.467.493 | 323.780 | 0,36% | Ações |
| MILLENNIUM MANAGEMENT LLC | $95.125.781 | 316.001 | 0,35% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $94.687.695 | 314.546 | 0,35% | Ações |
| Candriam S.C.A. | $94.586.456 | 314.512 | 0,35% | Ações |
| D. E. Shaw & Co., Inc. | $93.229.593 | 309.702 | 0,34% | Ações |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $90.367.000 | 300.193 | 0,33% | Ações |
| DEUTSCHE BANK AG\ | $89.849.026 | 298.472 | 0,33% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $88.641.294 | 294.460 | 0,33% | Ações |
| Pictet Asset Management Holding SA | $83.257.214 | 278.613 | 0,31% | Ações |
| BNP PARIBAS FINANCIAL MARKETS | $81.586.054 | 271.023 | 0,30% | Ações |
| GILDER GAGNON HOWE & CO LLC | $80.992.374 | 269.051 | 0,30% | Ações |
| CONGRESS ASSET MANAGEMENT CO | $79.983.972 | 265.701 | 0,29% | Ações |
| VANGUARD ASSET MANAGEMENT, Ltd | $77.578.441 | 257.710 | 0,29% | Ações |
| California Public Employees Retirement System | $76.477.575 | 254.053 | 0,28% | Ações |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $75.974.872 | 252.383 | 0,28% | Ações |
| Korea Investment CORP | $74.553.090 | 247.660 | 0,27% | Ações |
| Woodline Partners LP | $74.138.270 | 246.282 | 0,27% | Ações |
| Squarepoint Ops LLC | $70.440.719 | 233.999 | 0,26% | Ações |
| TD Asset Management Inc | $70.349.507 | 233.696 | 0,26% | Ações |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $65.136.061 | 196.863 | 0,24% | Ações |
| ROYAL LONDON ASSET MANAGEMENT LTD | $64.296.696 | 213.589 | 0,24% | Ações |
| National Pension Service | $59.692.744 | 198.295 | 0,22% | Ações |
| PINEBRIDGE INVESTMENTS LLC | $58.914.280 | 195.709 | 0,22% | Ações |
| Robeco Institutional Asset Management B.V. | $56.618.929 | 188.084 | 0,21% | Ações |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $53.824.164 | 178.800 | 0,20% | Opção de venda |
| VICTORY CAPITAL MANAGEMENT INC | $52.030.628 | 172.842 | 0,19% | Ações |
| Mitsubishi UFJ Asset Management Co., Ltd. | $50.772.924 | 168.664 | 0,19% | Ações |
| RHUMBLINE ADVISERS | $49.844.185 | 165.579 | 0,18% | Ações |
| Life Cycle Investment Partners Ltd | $49.797.587 | 165.424 | 0,18% | Ações |
| ANTIPODES PARTNERS Ltd | $49.228.339 | 163.533 | 0,18% | Ações |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $47.228.883 | 157.223 | 0,17% | Ações |
| CAPITAL FUND MANAGEMENT S.A. | $46.931.781 | 155.904 | 0,17% | Ações |
| Assenagon Asset Management S.A. | $46.868.866 | 155.695 | 0,17% | Ações |
| Vinva Investment Management Ltd | $45.487.381 | 154.972 | 0,17% | Ações |
| JANUS HENDERSON GROUP PLC | $43.671.202 | 132.000 | 0,16% | Ações |
| Hudson Bay Capital Management LP | $42.204.406 | 140.200 | 0,16% | Ações |
| ENVESTNET ASSET MANAGEMENT INC | $41.059.106 | 136.395 | 0,15% | Ações |
| ProShare Advisors LLC | $38.686.569 | 128.514 | 0,14% | Ações |
| GOLDMAN SACHS GROUP INC | $37.029.700 | 123.010 | 0,14% | Ações |
| LMR Partners LLP | $35.881.572 | 119.196 | 0,13% | Ações |
| Man Group plc | $35.798.187 | 118.919 | 0,13% | Ações |
| HSBC HOLDINGS PLC | $35.754.282 | 120.600 | 0,13% | Opção de venda |
| SCS Capital Management LLC | $34.783.715 | 115.549 | 0,13% | Ações |
| AVIVA PLC | $34.477.568 | 114.532 | 0,13% | Ações |
| Davern Capital Partners, LP | $34.041.978 | 113.085 | 0,13% | Ações |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $33.770.750 | 112.184 | 0,12% | Ações |
| Longaeva Partners L.P. | $33.191.869 | 110.261 | 0,12% | Ações |
| 683 Capital Management, LLC | $32.360.725 | 107.500 | 0,12% | Opção de venda |
| MARSHALL WACE, LLP | $32.215.929 | 107.019 | 0,12% | Ações |
| HighTower Advisors, LLC | $31.621.666 | 105.045 | 0,12% | Ações |
| Bridgewater Associates, LP | $29.977.772 | 99.584 | 0,11% | Ações |
| Prosight Management, LP | $29.525.022 | 98.080 | 0,11% | Ações |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $28.956.123 | 96.408 | 0,11% | Ações |
| Andra AP-fonden | $28.685.436 | 86.697 | 0,11% | Ações |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $28.376.894 | 94.266 | 0,10% | Ações |
| AMERIPRISE FINANCIAL INC | $28.191.159 | 93.649 | 0,10% | Ações |
| BARCLAYS PLC | $27.979.234 | 92.945 | 0,10% | Ações |
| TREMBLANT CAPITAL GROUP | $27.977.728 | 92.940 | 0,10% | Ações |
| FIL Ltd | $27.652.616 | 91.860 | 0,10% | Ações |
| Balyasny Asset Management L.P. | $26.945.195 | 89.510 | 0,10% | Ações |
| Caisse de depot et placement du Quebec | $25.812.720 | 85.748 | 0,10% | Ações |
| Mitsubishi UFJ Trust & Banking Corp | $24.911.136 | 82.753 | 0,09% | Ações |
| RAYMOND JAMES FINANCIAL INC | $24.661.883 | 81.925 | 0,09% | Ações |
| CITADEL ADVISORS LLC | $24.564.048 | 81.600 | 0,09% | Opção de compra |
| VANGUARD GROUP INC | $24.356.460 | 61.251 | 0,09% | Ações |
| NEOS Investment Management LLC | $23.562.822 | 78.274 | 0,09% | Ações |
| JONES FINANCIAL COMPANIES LLLP | $23.444.213 | 80.462 | 0,09% | Ações |
Executivos da empresa 41 insiders · 1 diretores · 13 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Melissa Mclaughlin | Chief Human Resources Officer | 6 de Abril de 2026 S | 9.443 | 0 | 14 | $-1.274.343 |
| Colleen F Reitan | Conselheiro | 20 de Maio de 2026 A | 1.446 | 0 | 0 | $0 |
| Charles Elliott Sigal | Conselheiro | 20 de Maio de 2026 A | 1.446 | 0 | 0 | $0 |
| Stuart A Arbuckle | Conselheiro | 20 de Maio de 2026 A | 671 | 0 | 0 | $0 |
| Olivier Brandicourt | Conselheiro | 20 de Maio de 2026 A | 1.446 | 0 | 0 | $0 |
| Amy Schulman | Conselheiro | 20 de Maio de 2026 A | 24.049 | 0 | 0 | $0 |
| Dennis A Ausiello | Conselheiro | 20 de Maio de 2026 A | 1.582 | 0 | 0 | $0 |
| Margaret A Hamburg | Conselheiro | 20 de Maio de 2026 A | 1.582 | 0 | 0 | $0 |
| KELLOGG PETER N | Conselheiro | 20 de Maio de 2026 A | 1.446 | 0 | 0 | $0 |
| David E I Pyott | Conselheiro | 20 de Maio de 2026 A | 1.582 | 0 | 0 | $0 |
| Victor J Dzau | Conselheiro | 21 de Junho de 2012 A | — | 0 | 0 | $0 |
| Peter Barrett | Conselheiro | 1 de Junho de 2006 A | 5.293 | 0 | 0 | $0 |
| John E Berriman | Conselheiro | 8 de Junho de 2005 A | 2.475 | 0 | 0 | $0 |
| Christoph H Westphal | Conselheiro | 3 de Junho de 2004 C | 2.409.970 | 0 | 0 | $0 |
| Sanofi | Detentor de 10% | 31 de Maio de 2017 P | 10.554.134 | 0 | 0 | $0 |
| ALNYLAM PHARMACEUTICALS, INC. | Detentor de 10% | 23 de Fevereiro de 2016 S | 4.896.716 | 0 | 0 | $0 |
| POLARIS VENTURE MANAGEMENT CO III LLC | Detentor de 10% | 3 de Junho de 2004 C | 2.409.970 | 0 | 0 | $0 |
| CHP II LP | Detentor de 10% | 27 de Maio de 2004 P | 232.500 | 0 | 0 | $0 |
| Akshay Vaishnaw | — | 10 de Agosto de 2018 A | 395 | 0 | 0 | $0 |
| Barry E Greene | — | 10 de Agosto de 2018 A | 9.030 | 0 | 0 | $0 |
| John Maraganore | — | 10 de Agosto de 2018 A | 151.297 | 0 | 0 | $0 |
| SHARP PHILLIP A | — | 9 de Março de 2018 M | 140.795 | 0 | 0 | $0 |
| Michael Mason | — | 4 de Janeiro de 2018 M | 0 | 0 | 0 | $0 |
| Laurie Keating | — | 29 de Dezembro de 2017 M | 14.500 | 0 | 0 | $0 |
| Yvonne Greenstreet | — | 20 de Dezembro de 2017 A | — | 0 | 0 | $0 |
| David-Alexandre C Gros | — | 20 de Dezembro de 2016 A | — | 0 | 0 | $0 |
| SCHIMMEL PAUL | — | 19 de Novembro de 2015 G | 306.996 | 0 | 0 | $0 |
| Marsha Fanucci | — | 1 de Junho de 2015 A | 10.000 | 0 | 0 | $0 |
| Steven M Paul | — | 1 de Junho de 2015 A | — | 0 | 0 | $0 |
| Michael W Bonney | — | 1 de Junho de 2015 A | — | 0 | 0 | $0 |
| John K Clarke | — | 1 de Junho de 2015 A | 2.091.868 | 0 | 0 | $0 |
| Kevin P Starr | — | 1 de Junho de 2015 A | — | 0 | 0 | $0 |
| Laurence Reid | — | 19 de Maio de 2014 M | 3.905 | 0 | 0 | $0 |
| Kenneth S Koblan | — | 8 de Dezembro de 2010 A | — | 0 | 0 | $0 |
| Patricia L Allen | — | 8 de Dezembro de 2010 A | 0 | 0 | 0 | $0 |
| James L Vincent | — | 18 de Junho de 2010 M | 0 | 0 | 0 | $0 |
| Vicki L Sato | — | 2 de Junho de 2010 A | — | 0 | 0 | $0 |
| Edward M Scolnick | — | 11 de Junho de 2009 A | — | 0 | 0 | $0 |
| John A Schmidt Jr | — | 9 de Dezembro de 2008 A | — | 0 | 0 | $0 |
| Vincent J Miles | — | 7 de Dezembro de 2005 A | — | 0 | 0 | $0 |
| Abingworth Management LTD | — | 3 de Junho de 2004 C | 18.745 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 2 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| CHP II, L.P. IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum ×2 declarações | 14 de Fevereiro de 2007 | — | Declaração inicial | — | SEC |
| CHP II, L.P IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum | 15 de Fevereiro de 2006 | — | Declaração inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 158 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 3,27% | 56.843 SH | 21 de Agosto de 2026 | Diário |
| NUMG · Nushares ETF Trust | 3,23% | 36.910 NS | 30 de Abril de 2026 | N-PORT |
| MID · AMERICAN CENTURY ETF TRUST | 3,19% | 10.523 NS | 31 de Maio de 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,79% | 3.791 NS | 31 de Maio de 2026 | N-PORT |
| FBT · First Trust Exchange-Traded Fund | 2,52% | 235.602 NS | 30 de Junho de 2026 | N-PORT |
| IBB · iShares Trust | 2,15% | 994.103 SH | 21 de Agosto de 2026 | Diário |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 2,01% | 3.468 NS | 30 de Abril de 2026 | N-PORT |
| BIB · ProShares Trust | 2,01% | 4.904 NS | 31 de Maio de 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,97% | 7.857 SH | 21 de Agosto de 2026 | Diário |
| QQEW · First Trust Exchange-Traded Fund | 1,96% | 117.806 NS | 30 de Junho de 2026 | N-PORT |
| FDG · AMERICAN CENTURY ETF TRUST | 1,94% | 26.515 NS | 31 de Maio de 2026 | N-PORT |
| QQXT · First Trust Exchange-Traded Fund | 1,86% | 10.248 NS | 30 de Junho de 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,40% | 824 NS | 30 de Abril de 2026 | N-PORT |
| CAML · Professionally Managed Portfolios | 1,29% | 15.623 NS | 30 de Abril de 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,24% | 2.379 NS | 30 de Abril de 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,14% | 1.954 NS | 31 de Maio de 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 1,08% | 966 NS | 30 de Abril de 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,90% | 15.151 NS | 30 de Abril de 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0,89% | 35.072 NS | 30 de Abril de 2026 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 0,88% | 1.022.888 SH | 19 de Agosto de 2026 | Diário |
| IWP · iShares Trust | 0,86% | 768.270 SH | 21 de Agosto de 2026 | Diário |
| JOET · Virtus ETF Trust II | 0,80% | 6.062 NS | 30 de Abril de 2026 | N-PORT |
| CGGR · Capital Group Growth ETF | 0,76% | 613.330 NS | 31 de Maio de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,66% | 60.901 NS | 30 de Abril de 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,59% | 398.693 SH | 19 de Agosto de 2026 | Diário |
| FFLG · FIDELITY COVINGTON TRUST | 0,58% | 11.032 NS | 30 de Abril de 2026 | N-PORT |
| QNXT · iShares Trust | 0,55% | 699 SH | 21 de Agosto de 2026 | Diário |
| USMV · iShares Trust | 0,50% | 521.451 SH | 21 de Agosto de 2026 | Diário |
| IYH · iShares Trust | 0,47% | 79.594 SH | 21 de Agosto de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,45% | 1.532.109 SH | 19 de Agosto de 2026 | Diário |
| UPSD · ETF Series Solutions | 0,44% | 1.435 NS | 30 de Abril de 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 0,43% | 4.118 NS | 31 de Maio de 2026 | N-PORT |
| FTXH · First Trust Exchange-Traded Fund VI | 0,42% | 510 NS | 30 de Junho de 2026 | N-PORT |
| IMCG · iShares Trust | 0,41% | 73.113 SH | 21 de Agosto de 2026 | Diário |
| QFLR · Innovator ETFs Trust | 0,39% | 6.430 NS | 30 de Abril de 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,39% | 2.893.468 SH | 19 de Agosto de 2026 | Diário |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,38% | 10.723 NS | 30 de Abril de 2026 | N-PORT |
| ESMV · iShares Trust | 0,37% | 128 SH | 21 de Agosto de 2026 | Diário |
| CVMC · Morgan Stanley ETF Trust | 0,37% | 1.248 NS | 30 de Junho de 2026 | N-PORT |
| SDG · iShares Trust | 0,34% | 2.658 SH | 21 de Agosto de 2026 | Diário |
| SMIZ · Zacks Trust | 0,31% | 2.688 NS | 31 de Maio de 2026 | N-PORT |
| ESLG · Strategy Shares | 0,31% | 196 NS | 30 de Abril de 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,31% | 112 NS | 30 de Abril de 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,30% | 305 NS | 30 de Abril de 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,28% | 94 NS | 31 de Maio de 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,26% | 404 NS | 30 de Abril de 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0,24% | 2.252 NS | 30 de Abril de 2026 | N-PORT |
| ESUM · Strategy Shares | 0,23% | 1.141 NS | 30 de Abril de 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,23% | 45.231 NS | 30 de Abril de 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,22% | 15.559 NS | 30 de Abril de 2026 | N-PORT |